20 February، 2022

Discussing the Research of the Iraqi Board (Mosul Centre) in Internal Medicine on the Effect and Safety of Ibrutinib for Patients with Chronic Lymphocytic Leukaemia

The student of the graduation paper of the Iraqi Board (Mosul Centre) in Internal Medicine, Sandy G. Ayo, discussed the effect and safety of the drug Ibrutinib for patients with chronic lymphocytic leukaemia in the city of Mosul / Iraq on Wednesday, 9th February 2022.

The aim of the research is to know the extent of the side effects of the mentioned drug for patients with chronic leukaemia in the city of Mosul.

It was concluded that this drug is a treatment option for patients with chronic lymphocytic leukaemia because it has acceptable proportions of side effects, and that treatment through it at an early stage reduces the burden of chemotherapy with high impact and high toxicity for elderly patients which leads to improving their quality of life.

The discussion committee consisted of Assistant Prof Dr Ismail D. Saeed (chairman), Prof Dr Imad A. Thanoun (member), Assistant Prof Dr Jassim M. Tayeb (member), and Prof Dr Khalid N. Al-Khairo (member and supervisor).

Part of the discussion was attended by the Dean of the College of Medicine, University of Mosul, Prof Dr Basil Mohammednather Saeed and the Official of the College’s Information Division.

After the discussion, the committee’s decision was read include accepting the research with the necessary amendments being made.

Share

Share